You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Accurate Characterization of Composite Strength Through Empirical and Progressive Damage Methods

    SBC: Atherotech, Inc.            Topic: N/A

    N/A

    SBIR Phase II 1996 Department of Health and Human Services
  2. A mechanism based computational tool to optimize pulmonary drug delivery

    SBC: CFD RESEARCH CORPORATION            Topic: 300

    DESCRIPTION provided by applicant Pulmonary drug delivery has emerged as a noninvasive alternative route for the treatment of lung diseases asthma COPD CF and lung cancer In order to obtain the desired level of effectiveness and safety of the inhaled drugs an appropriate deposition on the targeted region and subsequent absorption in the targeted region is vital Multiscale multidisciplin ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. A New Technique for Diabetic Foot Ulcers

    SBC: Noveratech L.L.C.            Topic: 200

    ABSTRACT Diabetes is the leading cause of nontraumatic lower extremity amputations in the United States Diabetic foot ulcers DFUs are responsible for more hospitalizations than any other diabetic complications Currently even the best available treatments achieve only a healing rate for these wounds and this healing is often only temporary with a chance of recurring Our company has ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. A Next Generation, Low Cost Tracking System for Healthcare

    SBC: Q-Track Corporation            Topic: 600

    DESCRIPTION provided by applicant The goal of the Phase I study is to determine the feasibility of piloting a low cost Real Time Location System RTLS for use in healthcare based on a novel technology known as Near Field Electromagnetic The proposed QHealth system promises to support a number of healthcare applications such as equipment management workflow optimization hand hygiene complian ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. An Innovative Device Integrating Cryopreservation, Storage, and Artificial Insemination of Mouse Sperm

    SBC: PARATECHS CORP            Topic: 100

    DESCRIPTION provided by applicant ParaTechs Corporation aims to provide researchers with advanced technology and methods to simplify procedures for laboratory animal models While actively supporting efforts to `reduce replace and refineandapos animal use ParaTechs provides safe and efficient alternatives for surgical procedures We have already brought to market a nonsurgical embryo transfe ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel Lipotherapy to Reduce Infarct Size Following Myocardial Infarction

    SBC: ENDOPROTECH, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant According to the CDC in ischemic heart disease is the leading cause of death worldwide and in the US approximately patients died of ischemic heart disease It is well established in clinical practice that recanalization of he infarct related artery IRA using percutaneous coronary intervention PCI enhances myocardial salvage and outcomes in pa ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. A Predictive In Vitro Model for Screening Personalized Responses to CFTR-directed Therapeutics

    SBC: CFD RESEARCH CORPORATION            Topic: NHLBI

    Abstract The objective of this study is to develop a novel predictive in vitro model for personalized responses to CFTR directed therapeutics This proposal responds to RFA HL Human Cellular Models for Predicting Individual Responses to Cystic Fibrosis Transmembrane Conductance Regulator Directed Therapeutics Cystic fibrosis CF is a life shortening genetic disease caused by loss of ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: 300

    DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of billions of dollars of healthcare spending annually It is common for bleeding from a single site to stop and restart multiple times The three modalities now used to diagnose and locate gastrointestina ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. A SORTING SYSTEM FOR IMPROVING THE QUALITY OF RECYCLED PET PLASTIC RESINS

    SBC: National Recovery Technologies LLC            Topic: N/A

    It is well known that post-consumer plastics have become a tremendous burden uponour waste disposal system. Although plastics constitute only about 9% by weightof municipal solid waste, they occupy approximately 1/4 the volume of the wastestream. A particular increasing problem for the recycling of PET is the growthin the use of very lightly tinted PET bottles, particularly light blue tintedbott ...

    SBIR Phase II 1996 Environmental Protection Agency
  10. A Toolkit for Pharmacotherapy of Dermally Administered Compounds

    SBC: CFD RESEARCH CORPORATION            Topic: FDA

    DESCRIPTION provided by applicant Delivery of therapeutic drugs via the dermal route is a promising alternative to oral or parenteral delivery routes Dermal drug delivery systems DS offer unique advantages which include controlled release over longer durations for steady absorption into the systemic circulation reduced systemic toxicity significant reduction in first pass effects and ga ...

    SBIR Phase I 2016 Department of Health and Human ServicesFood and Drug Administration
US Flag An Official Website of the United States Government